Lars Christian Wilde

President, Chief Business Officer, and Co-Founder

Lars is President, Chief Business Officer, and Co-Founder of COMPASS Pathways, focusing on operations, digital health solutions and fundraising.

Lars is also active as a business angel investor and advisor, and has helped to successfully build companies such as Otto Wilde Grillers and Emma & Noah. Before joining COMPASS, Lars was the founder and CEO of Springlane, the leading German kitchen equipment online retailer and the largest German cooking magazine. Being a hobby chef himself, Lars realised that cooking was moving from being a daily chore to becoming an interest for an increasingly large number of people. Exploiting this, Lars built Springlane from a two-person business into a company that produces its own brands and product ranges, is active in several European countries, runs offline retail stores, and has raised more than 30 million euros in capital from some of the leading European venture capital firms.

Lars previously worked as an investor at Waterland Private Equity, the world’s best performing private equity fund. Amongst other buy-and-build investments, he focused on building VivaNeo, the largest European in-vitro fertilization group, providing patients with cutting edge medical solutions. Lars has also spent time with Boston Consulting Group in Munich and São Paulo.

Lars holds a master’s degree in Finance with distinction from IE Business School in Spain and a Bachelor of Science in Business Administration with distinction from Rotterdam School of Management, Erasmus University in the Netherlands. Lars spent exchange semesters at Westfälische Wilhelms-Universität Münster, Copenhagen Business School and the Ross School of Business at the University of Michigan.

I have witnessed how devastating the impact of depression can be on a person’s life in my close circle of friends. My friend had the privilege of being treated with psilocybin and he has been relieved of the debilitating disease ever since. Unfortunately, this treatment is not available to most people in the world and its efficacy has yet to be proven in large-scale clinical trials. Having founded and invested in several companies in the past, I recognised that COMPASS offers the opportunity to build something immensely beneficial for our global society. I am excited by the outlook of solving one of humanity’s largest unmet medical needs together with an extremely smart and vision-driven team.